Todas las investigaciones
Activo, no reclutandoFASE2INTERVENCIONISTA

A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa

Infantile-onset Pompe disease is a rare condition that causes muscle weakness, breathing difficulties, and heart problems due to a missing enzyme. Children are usually treated with regular enzyme replacement therapy called alglucosidase alfa. However, for some children, this treatment stops working as well over time, or their symptoms begin to worsen. This clinical trial is testing a newer version of the enzyme medicine, called avalglucosidase alfa, in children aged 6 months to 17 years. The study aims to see if this medicine is safe and better at reaching the muscles that need it. Participants receive the medicine through a drip into a vein every two weeks. Because Pompe disease requires ongoing care, researchers will monitor the children's heart, lungs, and muscle strength over several years to understand the long-term benefits and safety.

De un vistazo

Estado
Activo, no reclutando
Fase
FASE2
Patrocinador
Genzyme, a Sanofi Company
Objetivo de inscripción
22
Inicio
12 Oct 2017
Estimación de finalización
10 Aug 2027

Resultados

Resultados de este estudio

Publicado November 2021

Se han publicado los resultados de este estudio.

Resultado principal
PAP: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Treatment-emergent Adverse Events, and Adverse Event of Special Interest (AESI)
Adverse event (AE): any untoward medical occurrence in participant received study drug \& did not necessarily had to have causal relationship with treatment. TEAEs: AEs developed/worsened in grade/become serious during PAP period (from the time of 1st study drug dose up to Week 25). Serious AE(SAE): any untoward medical occurrence at any dose resulted in death, was life-threatening, required inpatient hospitalization, prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was medically important event. TEAEs included SAEs \& non-SAEs. AESI:AE (serious/non-serious) of scientific \& medical concern specific to Sponsor's product/program, for which ongoing monitoring \& immediate notification by Investigator to Sponsor required.
Resultados completos en el registro

¿De qué trata este estudio?

Pompe disease is a rare, inherited condition where the body cannot make enough of an enzyme called acid alpha-glucosidase. Without this enzyme, a type of sugar called glycogen builds up inside the body's cells. Over time, this buildup damages muscles, particularly the heart and the muscles used for moving and breathing.

The standard treatment is enzyme replacement therapy using a medicine called alglucosidase alfa, given through a drip. While this treatment has saved many lives, some children find that their symptoms stop improving or begin to decline after a period of time. They may develop weaker muscles, extra breathing difficulties, or droopy eyelids.

This clinical study focuses on a modified treatment called avalglucosidase alfa. Scientists designed this newer medicine to be absorbed more easily by muscle cells, hoping it will clear glycogen more effectively. The study is investigating whether switching to this medicine can help stabilise or improve health in children whose current treatment is not giving the best results.

By following participants over several years, doctors hope to learn whether this treatment is safe for long-term use in children and how well it supports their day-to-day movement, breathing, and heart function.

Puntos clave

  • Tests a newer enzyme treatment for children with infantile-onset Pompe disease.
  • Aimed at young people whose current treatment is no longer working well enough.
  • Medicine is given through a drip once every two weeks.
  • Monitors heart, lung, and muscle health over several years.
  • Participation is completely voluntary and you can withdraw at any time.

¿Quién puede ser elegible?

This trial is for babies, children, and teenagers aged between 6 months and 17 years who have a confirmed diagnosis of infantile-onset Pompe disease. Participants must have had an enlarged heart (cardiomyopathy) when they were first diagnosed.

To take part, children must have already been receiving regular doses of the standard enzyme medicine (alglucosidase alfa) for at least six months. In addition, their doctor must have noticed that their condition is either declining or not improving as well as hoped in areas such as movement, breathing, heart function, or eyelid control.

Children cannot join the study if they have very high levels of antibodies against the enzyme therapy, or if they have a known high risk of severe allergic reactions to these types of treatments.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. Child is aged between 6 months and 17 years old.
  2. Has a confirmed diagnosis of infantile-onset Pompe disease.
  3. Had heart enlargement (cardiomyopathy) when first diagnosed.
  4. Has been on stable alglucosidase alfa treatment for at least six months.
  5. Shows signs of worsening symptoms or limited progress with current therapy.
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

Taking part in this study involves receiving the study medicine through an intravenous (IV) drip into a vein once every two weeks. Before treatment begins, your child will have a screening period lasting between two and four weeks to confirm that the study is safe and suitable for them.

The initial treatment period lasts 25 weeks, followed by a long-term extension period that can continue for several years. During clinic visits, the medical team will carry out regular health checks. These include blood tests, heart scans (such as echocardiograms), physical movement assessments, and breathing tests. After the treatment period ends, there is a four-week follow-up period to check on your child's wellbeing.

Riesgos y beneficios potenciales

The study medicine may help improve your child's muscle strength, breathing, and heart health more effectively than their previous treatment, but this cannot be guaranteed. As with any medicine given by a drip, there are potential side effects, such as allergic reactions, fever, skin rashes, or discomfort where the needle enters the vein. Your child will be watched closely by medical staff during and after each infusion. Taking part is completely voluntary, and you are free to withdraw your child from the study at any time without this affecting their standard NHS care.

Ubicaciones (12)

  • Regional Medical Genetics Center of New York Site Number : 8400002
    Código postal verificado
    Valhalla, United States
  • Duke University Medical Center Site Number : 8400001
    Código postal verificado
    Durham, Estados Unidos
  • Seattle Childrens Hospital and Regional Medical Center- Site Number : 8400005
    Código postal verificado
    Seattle, United States
  • Investigational Site Number : 2500004
    Código postal verificado
    Nantes, France
  • Investigational Site Number : 2500003
    Código postal verificado
    París, Francia
  • Investigational Site Number : 2500002
    Código postal verificado
    París, Francia
  • Investigational Site Number : 2500001
    Código postal verificado
    Tours, France
  • Investigational Site Number : 3920001
    Solo ciudad
    Fuchu-shi, Japan
  • Investigational Site Number : 3920002
    Solo ciudad
    Fuchu-shi, Japan
  • Investigational Site Number : 1580001
    Código postal verificado
    Hsinchu, Taiwan
  • Investigational Site Number : 8260001
    Código postal verificado
    Londres, Reino Unido
  • Investigational Site Number : 8260002
    Código postal verificado
    Manchester, Reino Unido

Preguntas comunes

How is the study medicine given?

It is given as an infusion through a drip into a vein once every two weeks at the study clinic.

Does my child have to stop their current treatment?

Children in this study will either switch to the new study medicine or be compared against standard treatment, depending on which group they enter. The study team will guide you through this process.

¿Cuánto tiempo estará mi hijo en el estudio?

Because Pompe disease requires lifelong management, this study includes a long-term follow-up that can last up to nine years, ensuring children receive continuous monitoring.

Will taking part cost us anything?

No, the study medicine and all trial-related tests are provided free of charge. Travel costs and related expenses are often covered by the study sponsor.

Can we leave the trial if we change our minds?

Yes, you can leave the study at any point. Deciding to withdraw will not affect your child's relationship with their doctors or their ongoing medical care.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.